COSM

Cosmos Health Inc.
NASDAQHEALTHCAREMEDICAL DISTRIBUTION

Key Statistics

Market Cap
$27.49M
P/E Ratio
EPS
$-0.67
Beta
4.17
52W High
$1.32
52W Low
$0.16
50-Day MA
$0.23
200-Day MA
$0.35
Dividend Yield
Profit Margin
-33.10%
Forward P/E
3.81
PEG Ratio
0.00

About Cosmos Health Inc.

Cosmos Holdings Inc. is a vertically integrated pharmaceutical company. The company is headquartered in Chicago, Illinois.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$73.73M
Gross Profit (TTM)$7.57M
EBITDA$-16.79M
Operating Margin-15.40%
Return on Equity-104.00%
Return on Assets-18.40%
Revenue/Share (TTM)$1.70
Book Value$0.26
Price-to-Book1.30
Price-to-Sales (TTM)0.37
EV/Revenue0.556
EV/EBITDA-1.60
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)28.80%
Shares Outstanding$100.63M
Float$78.78M
% Insiders21.68%
% Institutions3.67%

Historical Volatility

HV 10-Day
111.10%
HV 20-Day
99.82%
HV 30-Day
98.42%
HV 60-Day
114.43%
HV Rank
64.7%

Volatility is currently expanding

Analyst Ratings

Consensus ($4.50 target)

Latest News

Cosmos Health: A Company Transformed — 2026 Year-to-Date

A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026 Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) → Q1 2026 $17.93M (+31%) → Q2 2026 $18.99M (+28.8%) → H1 2026 $36.91M (+29.7%). Annualized adjusted run-rate exceeds $75M.

GlobeNewsWire9/3/2026Neutral
Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions

$8 million senior secured ATW convertible note satisfied, together with all accrued interest, twelve months ahead of its August 2027 maturity and eliminating any further dilution Simplified capital structure, with no effective shelf registration statement or ATM program, and no structured warrants or variable interest rate instruments without a floor Operating cash requirements reduced by more than 30%, reflecting revenue growth, operating efficiencies, improved operating leverage and cost control Strong liquidity position, with a diversified asset base supporting the Company's next growth phase and Bitcoin holdings now in a gain position following recent market strength $5.0 million share repurchase program underway, following record second-quarter and first-half revenue, with momentum continuing into Q3 2026 CHICAGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") ( NASDAQ: COSM ), a diversified, vertically integrated global healthcare group, today announced that its $8.0 million senior secured convertible ATW note has been retired, and provided an update on its capital structure and operating cash requirements. These financial milestones come at a time of accelerating growth, with Cosmos Health delivering its highest second-quarter and first-half revenue in Company history, contribution from every core division and momentum continuing into Q3 2026.

GlobeNewsWire8/28/2026Neutral
Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels

Digital subscription platform brings together the Company's proprietary consumer health products across consumer (B2C) and corporate (B2B) channels Customers can begin through one of three paths: a free nutritionist consultation, an AI-powered assistant, or building their own package Corporate offering supports employee wellness programs and corporate gifting through multi-recipient management, tiered volume pricing, centralized billing, and dedicated account management Future platform enhancements are expected to include AI-driven personalization and the potential integration of at-home testing and diagnostic kits Platform builds on the U.S. subscription launch of NOOR Collagen, which has delivered an early repeat purchase rate above 60% CHICAGO, July 27, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it is actively developing a flexible, technology-driven subscription platform for its consumer health products, representing a significant step in the Company's broader technology-driven transformation. Designed around customer choice, the platform will allow customers to begin with a free consultation with a nutritionist, engage with an AI-powered assistant, or select products and build their own package.

GlobeNewsWire7/27/2026Neutral
Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units

Cosmos Health expands its Sky Premium Life partnership with Pharma Cell in Albania, with average monthly orders already exceeding 4,500 units, and projected to exceed 54,000 annually Products are distributed across Albania and recommended by doctors and healthcare professionals, supporting broad consumer access Expansion builds on the partnership launched in April 2025 and reflects Sky Premium Life's continued global growth CHICAGO, July 20, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced an expansion of its partnership with Pharma Cell for the distribution of its Sky Premium Life brand in Albania. Building on the partnership the companies launched in April 2025, and reflecting the strong reception of Sky Premium Life in the Albanian market, the Company anticipates that orders under the expanded relationship will exceed 54,000 units on an annualized basis, with average monthly orders already exceeding 4,500 units.

GlobeNewsWire7/20/2026Neutral
Cosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market Repurchases

CHICAGO, July 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 274,000 shares of its common stock in the open market at an average price of approximately $0.2554 per share. The Company has now repurchased a total of 5,112,000 shares for approximately $1.11 million under its previously announced share repurchase program of up to $5 million.

GlobeNewsWire7/17/2026Neutral
Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases

CHICAGO, July 16, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 250,000 shares of its common stock in the open market at an average price of approximately $0.2782 per share. The Company has now repurchased a total of 4,838,000 shares for approximately $1.04 million under its previously announced share repurchase program of up to $5 million.

GlobeNewsWire7/16/2026Neutral
Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases

CHICAGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 100,000 shares of its common stock in the open market at an average price of approximately $0.2928 per share. The Company has now repurchased a total of 4,588,000 shares for approximately $970,000 under its previously announced share repurchase program of up to $5 million.

GlobeNewsWire7/15/2026Neutral
Cosmos Health Share Buyback Expands to 4.49 Million Shares; Continues Open Market Repurchases

CHICAGO, July 14, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 133,000 shares of its common stock in the open market at an average price of approximately $0.298 per share. The Company has now repurchased a total of approximately 4,488,000 shares for approximately $941,000 under its previously announced share repurchase program of up to $5 million.

GlobeNewsWire7/14/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on COSM and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/7/2026